Pfizer made over $211 million every day in the second quarter of this year despite its vaccine R&D was funded by taxpayers

Bill Gates once said that the best investment he has ever made was investing in vaccines. In 2019, CNBC wrote a piece titled, “My ‘best investment’ turned $10 billion into $200 billion worth of economic benefit.”

In an interview, Microsoft co-founder Bill Gates told CNBC that investing in global health organizations aimed at increasing access to vaccines creates a 20-to-1 return. “We feel there’s been over a 20-to-1 return,” yielding $200 billion over those 20 or so years,” Gates said.

Everyone would agree with Gates. There are currently no other better investments out there better than the business of selling mandated vaccines to millions of people and raking in millions of dollars with R&D funded by taxpayers and zero liability.

But Gates is not the only person getting richer with billions of dollars from the vaccine windfall. The big pharma has seen their stock prices gone through the roof in the past year. BioNTech, Moderna, and Pfizer are making billions from selling vaccines to billions of people around the world.

According to Pfizer’s second-quarter 2021 earning report, the pharmaceutical giant made $19 billion in Q2 this year, or $211 million per day. That’s not all, for those who may be experiencing side effects from the vaccines, Pfizer also sells Eliquis to treat blood clots, of which the sales have gone up 13 %. Pfizer also makes Vyndaqel to treat cardiomyopathy – sales are up 77%, according to the latest quarterly report.

Below is how Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla describes the blockbuster quarter:

“The second quarter was remarkable in a number of ways. Most visibly, the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented, with now more than a billion doses of BNT162b2 having been delivered globally.”

Bourla added:

“In addition, we are equally proud of the second-quarter performance of our business excluding BNT162b2(1), which posted 10% operational revenue growth. Looking forward, we remain highly confident in our ability to achieve at least a 6% compound annual growth rate through 2025 and intend to build upon our recent successes by continuing to follow the science, trust in our people, and remain focused on delivering breakthroughs for the patients we serve.”

Below is a PDF version of Pfizer’s Q2 earnings report.